Moderna Inc. and Merck & Co. said Wednesday that their personalized mRNA cancer vaccine succeeded in a Phase 3 trial for melanoma patients [1, 2].
The results represent a potential shift in oncology, as the treatment is tailored to the specific genetic profile of an individual's tumor to prevent the cancer from returning or spreading [3, 5].
The trial involved more than 1,000 patients [5]. By utilizing mRNA technology, the vaccine teaches the immune system to recognize and attack mutations unique to the patient's cancer cells. This personalized approach aims to reduce the likelihood of recurrence in patients who have already undergone primary treatment.
Financial markets reacted to the news on Wednesday. Moderna shares experienced a surge, with reports indicating the stock rose between 160 percent [1] and 177 percent [2] in intraday trading. Merck shares also saw gains, climbing more than 10 percent following the announcement [2].
While the companies highlighted the efficacy of the vaccine in reducing the spread of the disease, the partnership between the two biotech giants leverages Moderna's mRNA platform and Merck's experience in immunotherapy. The trial data suggests that the combination of these technologies provides a more precise strike against melanoma than traditional broad-spectrum treatments [3, 4].
This milestone follows years of research into mRNA applications beyond infectious diseases. The success of this large-scale trial provides a blueprint for developing similar personalized vaccines for other types of malignant tumors, a goal both companies have pursued since the beginning of their collaboration [3, 5].
“The vaccine is personalized to each patient’s tumor genetic profile.”
The success of a Phase 3 trial indicates that the vaccine is moving closer to regulatory approval and widespread clinical use. By proving that mRNA can be effectively personalized for oncology, Moderna and Merck have validated a model that could potentially be applied to various other cancers, shifting the treatment paradigm from general chemotherapy toward precision immunotherapy.
